Researchers at Johns Hopkins have found out the use of psychedelic 5-methoxy-N,-N-dimethyltryptamine and it appears to be related with unintentional betterment in self-reported anxiety and depression. 5-MeO-DMT is a psychoactive present in the venom of Bufo Alvarius, some plants species, and can also be made synthetically.
In a survey conducted of 362 adults, roughly 80% of the people reported that it helped with depression and anxiety. A stronger belief that the experiment would prove beneficial also helped in improvement.
A postdoctoral student, Dr. Alan K. Davis said, “Research has shown that psychedelics given alongside psychotherapy help people with depression and anxiety. However, psychedelic sessions usually require 7 – 8 hours per session because psychedelics typically have a long duration of action. Because 5-MeO-DMT is short-acting and lasts approximately 30-90 minutes, it could be much easier to use as an adjunct to therapy because current therapies usually involve a 60 – 90-minute session.”
At the end of last year, Mr. Alan K. Davis had presented another study on the topic, Frontiers in Psychology. The study observed that the 5-MeO-DMT was administering a psychospiritual. Another work of Davis was published in The Journal of Psychopharmacology last year. It clearly showed safe profile usage and very small risk in the health consequences of 5-MeO-DMT.
Davis said, “It is important to examine the short- and long-term effects of 5-MeO-DMT, which may enhance mood in general or maybe particularly mood enhancing for those individuals experiencing clinically significant negative mood. Regardless, this research is in its infancy and further investigation is warranted in healthy volunteers.”
The writers of this study are Alan K. Davis, Roland R. Griffiths, and Sara So from Johns Hopkins, Mr. Joseph P. Barsuglia from the New School Research and Rafael Lancelotta from the University of Wyoming.